| Registry | NCT07631559 |
|---|---|
| Status | Not yet recruiting |
| Phase | Not applicable |
| Study type | Interventional; na, single group, masking: none, other |
| Enrollment | 50 (Estimated) |
| Sponsor | University of California, San Francisco (Other); collaborators: National Institute on Drug Abuse (NIDA) |
| Conditions | HEPATITIS C (HCV), Opioid Use Disorder, Substance Use Disorder (SUD), Drug Use Disorders, Healthcare Access, Harm Reduction |
| Interventions | Partner navigation intervention booster session (Behavioral) |
| Dates | start 2026-09-01 (estimated), primary completion 2027-03-01 (estimated), completion 2027-06-30 (estimated), first posted 2026-06-08, last updated 2026-06-08 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
All trials for HEPATITIS C (HCV) All trials for Opioid Use Disorder All trials of Partner navigation intervention booster session
This study builds upon an ongoing NIH-funded randomized controlled trial (R01DA053325) evaluating a Partner Navigation Intervention to increase hepatitis C virus (HCV) treatment initiation among young adult people who inject drugs (PWID) and their injecting partners in San Francisco. The proposed research includes secondary analyses of existing trial data, additional survey measures, qualitative interviews, and a pilot intervention adaptation.
The study has two primary objectives. First, it examines how racialized discrimination (structural, interpersonal, and internalized) affects HCV treatment initiation and dyadic partner support processes within injecting partnerships. Second, it evaluates whether a brief, adapted "booster" partner navigation session delivered at HCV treatment completion can improve engagement in ongoing healthcare.
Participants include adults (≥18 years) who inject drugs and have been diagnosed with HCV, along with their primary injecting partners. Study activities include longitudinal surveys, qualitative interviews with a subset of participants, and a pilot intervention session with follow-up evaluation.
This research addresses critical gaps in understanding how social relationships and structural inequities influence healthcare engagement among PWID. Findings will inform culturally responsive adaptations to dyadic interventions and improve continuity of care in a population disproportionately affected by HCV and systemic barriers to healthcare.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Partner Navigation Booster Session | Experimental | Behavioral: Partner navigation intervention booster session | Injecting dyads (index participant and their primary injecting partner) receive one adapted Partner Navigation Intervention booster session at the point of HCV treatment completion, designed to strengthen partnership-based support for sustained healthcare engagement beyond HCV care. |
Sex: All, ages: 18 Years to any
Inclusion criteria: For index participants: * 18 years of age or older at enrollment * History of injecting drug use * Completed HCV treatment within the past 3 months * Report a primary injecting partner willing to participate * Willing and able to provide informed consent * English or Spanish speaking For primary injecting partners: * Primary injecting partner of an enrolled index participant: * 18 years of age or older at enrollment * Willing and able to provide informed consent * English or Spanish speaking * has context menu Exclusion criteria: For both index participants and injecting partners: * Unable to provide informed consent due to cognitive impairment or acute intoxication at the time of enrollment * Previously participated in this study in any capacity
| Facility | City | Country | Status |
|---|---|---|---|
| Quaker Meeting House | San Francisco, California | United States |
NIH grants: K24DA061103